Elad Kedar, Orasis CEO (Orasis)
Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII
Orasis Pharmaceuticals is one of several biotechs developing miotic-based eye drops as a potential alternative to reading glasses — one drop, and no more squinting at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.